The UK pharmaceutical giant GlaxoSmithKline (GSK) announced on Monday that it has started the final trials of its new shingles vaccine.
The pharma company plan to include more than 30,000 patients worldwide in the Phase III trial.
In a statement, Norman Begg, Chief Medical Office at GSK Biologicals, said, “Shingles is an often debilitating condition for which there are limited treatment and prevention options.
“That is why progression into late stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need.”
Shingles is caused by the varicella-zoster virus and results in a painful rash on one side of the body.
GSK’s shares rose 1% — or 15p — to 1221.5p after it said it was rolling out a stage three trial to more than 30,000 patients.
Are you looking for your next role within the pharmaceutical industry? Click here to search our current pharmaceutical jobs now.